{"nctId":"NCT00165698","briefTitle":"Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women","startDateStruct":{"date":"2005-05"},"conditions":["Postmenopausal Osteoporosis"],"count":240,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: menatetranone"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: alfacalcidol"]}],"interventions":[{"name":"menatetranone","otherNames":[]},{"name":"alfacalcidol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria :\n\n* Postmenopausal women with menopause duration more than 5 years and with age between 45-75 years old (menopausal age ≥40), or if hysterectomy operated before natural menopause, the age of women between 60-75 years old.\n* Subject with BMD (L2-4 or neck of femur) being more than 2 Standard Deviation (SD) below the young female adult mean (According to the standard of each center)\n* BMI between 18 kg/m2-30 kg/m2.\n* The anatomic structure of lumbar spine must be available for Dual-energy X-ray Absorptiometry (DEXA) examination, patient with serious scoliosis, bone trauma or sequela after orthopedics surgery, which makes BMD measurement difficult, should be excluded\n* Subject who have given informed consent prior to participation in the trial and who undertake to comply with the protocol.\n\nExclusion Criteria\n\n* Subject with conditions that are considered to effect osteoporosis, such as clear definite diabetes mellitus, rheumatoid arthritis, rheumatoid arthritis, hyperparathyroidism or other bone metabolic diseases.\n* Subjects who have received treatment with active-type vitamin D3 preparation, other vitamin D preparations (\\>1000IU per day）, calcitonin, corticosteroid hormone, androgen, estrogen, other hormone, vitamin K preparation, in the 3 months prior to inanition of this study; Subjects who have received treatment with bisphosphonate preparation or Sodium Fluoride in the 1 year prior to inanition of this study; Subjects who have received treatment with Selective Estrogen Receptor Modulator (SERM) in the 6 months prior to inanition of this study\n* Concurrent serious renal disease, hepatic disease, uncontrolled hypertension （≥150/100mmHg）, symptomatic ischemic heart disease, cerebral infarction or arteriosclerosis obliterans.\n* Cancer history within 5 years.\n* Subjects who take antacid containing aluminum in the preparation, warfarin or thrombolytic agents.\n* Subject with any known abnormality in laboratory tests, which is deemed to be clinically significant by the investigator, which include:\n* Serum alkaline phosphatace (ALP) \\> upper normal limit 10% (calculated according to the range of normal values of each center);\n* Glutamic Oxalacetic Transaminase (AST)/ Glutamic Pyruvic Transaminase (ALT) \\> upper normal limit 50％(calculated according to the range of normal values of each center);\n* Serum creatinine \\>1.5mg/dL (133μmol/L);\n* Blood-fasting sugar ≥ 7mmol/L (126mg/L)\n* Inability of subject to return for scheduled visits or to comply with any other aspect of the protocol.\n* Subject who, in the opinion of the investigator, are poor medical candidates or pose any other risk for therapy with an investigational drug.","sex":"FEMALE","minimumAge":"45 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":null},{"groupId":"OG001","value":"2.17","spread":null}]}]}]},{"type":"PRIMARY","title":"Bone Mineral Density BMD (Percentage) Change in Collum Femoris After 12 Months","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"PRIMARY","title":"Bone Mineral Density BMD (Percentage) Change in Trochiter After 12 Months","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.66","spread":null},{"groupId":"OG001","value":"1.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Bone Mineral Content BMC (Percentage) Change in Lumber Spine After 12 Months","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":null},{"groupId":"OG001","value":"2.81","spread":null}]}]}]},{"type":"SECONDARY","title":"Bone Mineral Content BMC (Percentage) Change in Collum Femoris After 12 Months","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.58","spread":null},{"groupId":"OG001","value":"0.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Bone Biomarker Osteocalcin (OC) Percentage Change After 12 Months","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.67","spread":null},{"groupId":"OG001","value":"-25.77","spread":null}]}]}]},{"type":"SECONDARY","title":"Bone Biomarker Undercarboxylated Osteocalcin (UCOC) Percentage Change After 12 Months","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-82.27","spread":null},{"groupId":"OG001","value":"-34.83","spread":null}]}]}]},{"type":"SECONDARY","title":"Bone Biomarker Undercarboxylated Osteocalcin/Osteocalcin (UCOC/OC) Percentage Change After 12 Months","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-70.64","spread":null},{"groupId":"OG001","value":"-8.47","spread":null}]}]}]},{"type":"SECONDARY","title":"New Fracture and Fall","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Height (Meter)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":"0.05"},{"groupId":"OG001","value":"1.55","spread":"0.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":"0.06"},{"groupId":"OG001","value":"1.55","spread":"0.05"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":117},"commonTop":["Gastrointestinal disorders","Respiratory abnormalities","Others","Musculoskeletal system abnormalities","Abnormal Cardiovascular system"]}}}